In order to explore in vivo differences in the composition of type I IFN signatures in autoimmune diseases, we studied IRG expression profiles of a prototype IFNα-driven disease, i.e., SLE, and those of MS patients who were treated with IFNβ for 3 months. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.